Click here to navigate
- Conditions of sale
- Related products
Results are for the identification of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in upper respiratory specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient’s infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.
The iAMP COVID-19 SANO Assay is intended for use by trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time nucleic acid amplification and in vitro diagnostic procedures.
* The iAMP COVID-19 Sample Collection Device and iAMP COVID-19 Sample Collection Device NP are for Research Use Only; not for use in diagnostic procedures. Not yet available as CE marked product.
Conditions of sale
To read the end user conditions of sale for this product please visit our Resource center.
InsightsJan 6, 2022Oct 15, 2020
FAQHow does the coronavirus disease Covid-19 impact Fujirebio's operations?
Please see the following statement on the impact of coronavirus disease Covid-19 on the operations of Fujirebio Europe (updated January 19, 2021).